Evaluation of KIM-1 and NGAL as early indicators for assessment of gentamycin-induced nephrotoxicity in vivo and in vitro
N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction
While there is no standard indication for the duration of use, most clinical trials last from one to several weeks
Retatrutide is currently under phase 3 FDA clinical trials by Eli Lilly
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, et al: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons